EMA begins rolling review of another Covid-19 vaccine

The European Medicines Agency will assess the potential vaccine being developed by Valneva as data trickles in.

Photo: Stephane Mahe/REUTERS / X02520

The European Medicines Agency (EMA) has initiated a rolling review for biotech company Valneva's Covid-19 vaccine candidate, the EMA announces in a news release.

This means that Valneva can submit data in smaller chunks, instead of having to deliver a full data package to the EMA, cutting down on case processing overall.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs